RAINBOW: A GLOBAL, PHASE 3, DOUBLE-BLIND STUDY OF RAMUCIRUMAB (RAM) PLUS PACLITAXEL (PTX) VERSUS PLACEBO (PL) plus PTX IN THE TREATMENT OF ADVANCED GASTRIC AND GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA FOLLOWING DISEASE PROGRESSION ON FIRST-LINE PLATINUM- AND FLUOROPYRIMIDINE-CONTAINING COMBINATION THERAPY: A SUBGROUP ANALYSIS OF WESTERN POPULATION

被引：0

作者：

Wilke, Hansjochen ^{[1
]}

Clingan, Philip ^{[2
]}

Ananda, Sumi ^{[3
]}

Kurteva, Galina ^{[4
]}

Suuroja, Tiit ^{[5
]}

Folprecht, Gunnar ^{[6
]}

Beny, Alexander ^{[7
]}

Pastorelli, Davide ^{[8
]}

Cesas, Alvydas ^{[9
]}

Nowecki, Zbigniew ^{[10
]}

Toganel, Cornelia ^{[11
]}

Bodoky, Gyoergy ^{[12
]}

Lipatov, Oleg ^{[13
]}

Miron, Maria Limon ^{[14
]}

Cunningham, David ^{[15
]}

Cummins, Sebastian ^{[16
]}

Wainberg, Zev ^{[17
]}

Ko, Andrew ^{[18
]}

Emig, Michael ^{[19
]}

Chandrawansa, Kumari ^{[20
]}

van Cutsem, Eric ^{[21
]}

机构：

[1] Kliniken Essen Mitte, Essen, Germany

[2] Southern Med Day Care Ctr, Wollongong, NSW, Australia

[3] Western Hlth, Melbourne, Vic, Australia

[4] Specialised Hosp Act Treatment Oncol, Sofia, Bulgaria

[5] North Estonia Med Ctr, Tallinn, Estonia

[6] Univ Klinikum Carl Gustav Carus, Dresden, Germany

[7] Rambam Hlth Care Campus, Haifa, Israel

[8] Ist Oncol Veneto IRCCS, Padua, Italy

[9] Klaipeda Univ Hosp, Klaipeda, Lithuania

[10] Ctr Onkol Inst M Sklodowskiej Curie, Warsaw, Poland

[11] Spitalul Clin Judetean Mures, Targu Mures, Romania

[12] St Laszlo Hosp, Dept Oncol, Budapest, Hungary

[13] Republican Clin Oncol Dispensary, Ufa, Russia

[14] HUV Rocio, Seville, Spain

[15] Royal Marsden Hosp, London SW3 6JJ, England

[16] Royal Surrey Cty Hosp, Guildford, Surrey, England

[17] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA

[18] Univ Calif San Francisco, San Francisco, CA 94143 USA

[19] Eli Lilly & Co, Homburg, Germany

[20] Eli Lilly & Co, Indianapolis, IN 46285 USA

[21] Univ Hosp Gasthuisberg Leuven, Leuven, Belgium

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 10卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

362

引用

页码：171 / 171

页数：1

共 45 条

[21] Age subgroup analysis of efficacy and safety data from two phase 3 studies of second-line ramucirumab (RAM) versus placebo (PL) in patients (pts) with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINBOW and REGARD) [J].

Cascinu, S. ;

Aprile, G. ;

Pastorelli, D. ;

Pinto, C. ;

Bordonaro, R. ;

Farina, G. ;

Amoroso, D. ;

Bilancia, D. ;

Ciuffreda, L. ;

Sartori, D. ;

Falcone, A. ;

Silvestris, N. ;

Beretta, G. D. ;

Buonadonna, A. ;

Sobrero, A. ;

Tamburini, E. ;

Amoroso, V. ;

Hsu, Y. ;

Chandrawansa, K. ;

Wilke, H. ;

Fuchs, C. ;

Passalacqua, R. .

ANNALS OF ONCOLOGY, 2015, 26 :90-90

[22] KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma [J].

Tabernero, J. ;

Bang, Y. ;

Van Cutsem, E. ;

Fuchs, C. ;

Janjigian, Y. ;

Bhagia, P. ;

Li, K. ;

Adelberg, D. ;

Qin, S. .

ANNALS OF ONCOLOGY, 2020, 31 :S101-S102

[23] A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859 [J].

Qin, S. ;

Tabernero, J. ;

van Cutsem, E. ;

Fuchs, C. S. ;

Janjigian, Y. Y. ;

Bhagia, P. ;

Li, K. ;

Adelberg, D. ;

Bang, Y-J. .

ANNALS OF ONCOLOGY, 2020, 31 :S1316-S1317

[24] Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised multicentre, double-blind, phase 3 trial [J].

Xu, Rui-Hua ;

Zhang, Yanqiao ;

Pan, Hongming ;

Feng, Jifeng ;

Zhang, Tao ;

Liu, Tianshu ;

Qin, Yanru ;

Qin, Shukui ;

Yin, Xianli ;

Liu, Baorui ;

Ba, Yi ;

Yang, Nong ;

Voon, Pei Jye ;

Tanasanvimon, Suebpong ;

Zhou, Chan ;

Li Zhang, Wan ;

Shen, Lin .

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (12) :1015-1024

[25] Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study [J].

Valle, Juan W. ;

Bai, Li-Yuan ;

Orlova, Rashida ;

Van Cutsem, Eric ;

Alfonso, Jorge Adeva ;

Chen, Li-Tzong ;

Obermannova, Radka ;

Ettrich, Thomas Jens ;

Chen, Jen-Shi ;

Wasan, Harpreet Singh ;

Denlinger, Crystal S. ;

Vogel, Arndt ;

He, Aiwu Ruth ;

Bousmans, Nathalie ;

Girvan, Allicia C. ;

Zhang, Wei ;

Walgren, Richard A. ;

Carlesi, Roberto ;

Oh, Do-Youn .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)

[26] Quality-of-life (QoL) results from RAINFALL: A randomized, double-blind, placebo (PL)-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy for metastatic gastric or gastroesophageal junction (G-GEJ) cancer [J].

Chau, I. ;

Al-Batran, S-E. ;

Luft, A. ;

Kowalyszyn, R. D. ;

Hernandez, C. A. ;

Pfeiffer, P. ;

Wojcik, E. ;

Bodoky, G. ;

Madi, A. ;

Brenner, B. ;

De Vita, F. ;

Folprecht, G. ;

Peltola, K. ;

Lorenzen, S. ;

Denlinger, C. ;

Liepa, A. ;

Das, M. ;

Wei, R. ;

Fuchs, C. S. .

ANNALS OF ONCOLOGY, 2018, 29

[27] Subgroup analysis by KRAS status in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression during or following first-line combination therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine [J].

Van Cutsem, E. ;

Obermannova, R. ;

Bodoky, G. ;

Prausova, J. ;

Garcia-Carbonero, R. ;

Ciuleanu, T. ;

Garcia Alfonso, P. ;

Portnoy, D. ;

Cohn, A. ;

Yamazaki, K. ;

Clingan, P. ;

Yoshino, T. ;

Polikoff, J. ;

Lonardi, S. ;

Macarulla, T. ;

Yang, L. ;

Nasroulah, F. .

EUROPEAN JOURNAL OF CANCER, 2015, 51 :S365-S365

[28] REGARD phase III, randon ed, double-blinded trial of mum ib and best supportive care (BSC) versus placebo and BSC in the Ireattneiti of metasta lie gastric or gastroesophageal junction (GEJ) adenocarcino u following disease progression on first-line platinum- and/or fluorop., midine-containing combination therapy. [J].

Fuchs, Charles S. ;

Tomasek, Jiri ;

Cho, Jae Yong ;

Dumitru, Filip ;

Passalacqua, Rodolfo ;

Goswami, Chanchal ;

Safran, Howard ;

dos Santos, Lucas Vieira ;

Aprile, Giuseppe ;

Ferry, David R. ;

Melichar, Bohuslav ;

Tehfe, Mustapha ;

Topuzov, Eldar ;

Tabemero, Josep ;

Zalcberg, John Raymond ;

Chau, Ian ;

Koshiji, Minori ;

Hsu, Yanzhi ;

Schwartz, Jonathan D. ;

Ajani, Jaffer A. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)

[29] RILOMET-1: An international phase III multicenter, randomized, double-blind, placebo-controlled trial of rilotumumab plus epirubicin, cisplatin, and capecitabine (ECX) as first-line therapy in patients with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma [J].

Cunningham, David ;

Al-Batran, Salah-Eddin ;

Davidenko, Irina ;

Ilson, David H. ;

Murad, Andre M. ;

Tebbutt, Niall C. ;

Jiang, Yizhou ;

Lou, Elwyn ;

Dubey, Santa .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

[30] A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The RILOMET-2 trial [J].

Doi, Toshihiko ;

Kang, Yoon-Koo ;

Muro, Kei ;

Jiang, Yizhou ;

Jain, Rajul K. ;

Lizambri, Richard .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)

← 1 2 3 4 5 →